Baby steps on the road to HIV eradication

New England Journal of Medicine

Volumn 369, Issue 19, 2013, Pages 1855-1857

  Hammer, Scott M ^a  

^a NewYork Presbyterian Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR5; VIRUS DNA; VIRUS RNA;

ACUTE GRANULOCYTIC LEUKEMIA; CARDIOVASCULAR DISEASE; CD4+ T LYMPHOCYTE; CELL TYPE; DRUG EFFICACY; EDITORIAL; ERADICATION THERAPY; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; KIDNEY DISEASE; LIFE EXPECTANCY; LIVER DISEASE; MALIGNANT NEOPLASTIC DISEASE; MORBIDITY; MORTALITY; NONHUMAN; PRENATAL CARE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT RESPONSE; VIREMIA; VIRUS CARRIER; VIRUS CELL INTERACTION; VIRUS RELEASE; VIRUS REPLICATION; VIRUS TRANSMISSION; WELLBEING;

EID: 84887092015     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe1309006     Document Type: Editorial

References (11)

1. Thompson MA, Aberg JA, Hoy JF, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 2012;308:387-402.
2. Siliciano JD, Siliciano RF. HIV-1 eradication strategies: design and assessment. Curr Opin HIV AIDS 2013;8:318-25.
3. Hütter G, Nowak D, Mossner M, et al. Long-term control of HIV by CCR5 delta32/delta32 stem-cell transplantation. N Engl J Med 2009;360:692-8.
4. Yukl SA, Boritz E, Busch M, et al. Challenges in detecting HIV persistence during potentially curative interventions: a study of the Berlin patient. PLoS Pathog 2013;9(5):e1003347.
5. Henrich TJ, Hu Z, Li JZ, et al. Long-term reduction in peripheral blood HIV type 1 reservoirs following reduced-intensity conditioning allogeneic stem cell transplantation. J Infect Dis 2013;207:1694-702.
6. Ananworanich J, Schuetz A, Vandergeeten C, et al. Impact of multi-targeted antiretroviral treatment on gut T cell depletion and HIV reservoir seeding during acute HIV infection. PLoS One 2012;7(3):e33948.
7. Sáez-Cirión A, Bacchus C, Hocqueloux L, et al. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog 2013;9(3):e1003211.
8. Persaud D, Gay H, Ziemniak C, et al. Absence of detectable HIV-1 viremia after treatment cessation in an infant. N Engl J Med 2013;369:1828-35.
9. Archin NM, Liberty AL, Kashuba AD, et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 2012;487:482-5. [Erratum, Nature 2012;489:460.]
10. Shan L, Deng K, Shroff NS, et al. Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity 2012;36:491-501.
11. Kent SJ, Reece JC, Petravic J, et al. The search for an HIV cure: tackling latent infection. Lancet Infect Dis 2013;13:614-21.